youRINALTRACT Infections (UTIS) is one of the most common medical problems that women experience. Maximum 60% Women will get one for a lifetime. The lower the estrogen level, the more the level of the beneficial bacteria that suppress infection bacteria can decrease, so women after the menopause are especially sensitive.
On March 25, the US Food and Drug Administration (FDA) approved the first new antibiotic that treated UTI in 30 years. Drugs, crayfotida, target E. coli Bacteria, which are responsible for the most common types of infections, are not complex UTI, affect women.
The drug, called Blujepa, works differently from existing antibiotics. It targets two enzymes E. coli It is used to create more copies when creating and snapping DNA circles. In this process, DNA can be a knot, but bacteria can cancel the knot. Blujepa interferes with the process and prevents bacteria from replicating and creating more bacteria that can infect cells.
Read more: The menopause is finally becoming mainstream
GSK’s chief scientific officer (creating Blujepa) Tony Wood said that this process is unique in the media briefing. E. coli The fact that bacteria and drugs focus on this unique characteristics can make it more difficult for bacteria to show resistance to the drug. Existing antibiotics used to treat UTI have extensive activity for multiple bacterial species. This is likely to find a way for bacteria to develop resistance to them.
In the two large -scale tests of the drug reviewed by the FDA for approval, the Blujepa was superior to or slightly better than other general prescribed antibiotics for UTIS and Nitrofurantoin. Blujepa has successfully treated 50%and 58%of women, compared to Nitrofurantoin’s 43%and 47%in two studies on infections, respectively.
GSK is also studying drugs for other drugs. E. coli Wood has an infection of the body, including gonorrhea, Wood says.
In addition, the company is studying other antibiotics to treat complex UTIs, where the infection spreads beyond the bladder to another. This infection often requires hospitalization and longer treatment. The drug can potentially help people get out of the hospital or reduce their stay if they need more intensive treatment.
